Artemisinin combination therapy market garnered a revenue of USD 396.23 million in the year 2019 globally and has been foreseen to grow at a compound annual growth (CAGR) of 7.3% over the forecast period. The market has been observed to be growing at a steady growth rate over the last three years, however with the impact of COVID-19 pandemic globally, the business conditions are expected to change. The market size may reduce significantly or increase with a spike depending on how the value chain has been affected in the entire process.
Players that are operational in the market for a longer period of time are anticipated to absorb the sudden changes, losses and increased operational costs better than those who have recently entered the market. The report focuses on numerous factors that are anticipated to impact the market growth directly and indirectly. The report categorically analyses the growth patterns of different segments based on multiple derivation models.
Both the qualitative and quantitative aspects have been covered under the report. The Artemisinin Combination Therapy market report includes market size, drivers, restraints, opportunities and trends that will help you understand the market dynamics in detail. Moreover, the report will include market estimates & forecasts in terms of revenue for the overall market along with the segments mentioned in the study. The report focuses on providing a holistic view of the entire market scenario from multiple unmatched detailed analysis mentioned in the report.
What to expect from the report?
Artemisinin Combination Therapy Total Available Market (TAM) Size
Artemisinin Combination Therapy Serviceable Available Market (SAM) Size
Business Implications of COVID-19 on the Overall Market
Market Share/ Revenue Share (%) of Top Market Players in Total Market Size (2019)
Market Size & Forecast (2016-2027) At Country & Regional Level, By Segments
Overview & Analysis of Key Players Operating in the Market
Global market revenue in 2020 will be derived taking into various micro & macro level factors; along with COVID-19 pandemic
Competitive Analysis
Company Market Share Analysis, 2019 (%)
Supply Chain Analysis
Analysis pertaining to several participants of supply chain such as raw material suppliers, distributors, & OEMs along with others will be highlighted in the study
Data Source
Primary & Secondary Research, Internal Data Base & Company Annual Reports
Regions Included
North America, Europe, Asia Pacific, Latin America, & Middle East & Africa
Countries Included
U.S., Canada, U.K., Germany, France, Mexico, Brazil, China, India, Japan, South Korea, UAE, South Africa
Table of Contents Chapter 1. Research Methodology & Data Sources 1.1. Data Analysis Models 1.2. Research Scope & Assumptions 1.3. List of Primary & Secondary Data Sources Chapter 2. Executive Summary Chapter 3. Artemisinin Combination Therapy Market: Industry Analysis 3.1. Market segmentation 3.2. Supply chain analysis 3.3. Porter’s 5 forces analysis 3.4. PEST analysis 3.5. Market Dynamics 3.5.1. Market driver analysis 3.5.2. Market restraint analysis 3.5.3. Market opportunity analysis 3.6. Company Market Share Analysis, 2019 Chapter 4. Artemisinin Combination Therapy Market: Type Insights 4.1. Global Type Historic Market Data & Future Forecasts, 2016-2027 4.2. Pyronaridine-Artesunate 4.2.1. Historic Market Data & Future Forecasts, 2016-2027 4.2.2. Historic Market Data & Future Forecasts by Region, 2016-2027 4.3. Artesunate+Sulfadoxine-Pyrimethamine 4.3.1. Historic Market Data & Future Forecasts, 2016-2027 4.3.2. Historic Market Data & Future Forecasts by Region, 2016-2027 4.4. Artesunate+Mefloquine 4.4.1. Historic Market Data & Future Forecasts, 2016-2027 4.4.2. Historic Market Data & Future Forecasts by Region, 2016-2027 4.5. Dihydroartemisinin+Piperaquine 4.5.1. Historic Market Data & Future Forecasts, 2016-2027 4.5.2. Historic Market Data & Future Forecasts by Region, 2016-2027 4.6. Artesunate+Amodiaquine 4.6.1. Historic Market Data & Future Forecasts, 2016-2027 4.6.2. Historic Market Data & Future Forecasts by Region, 2016-2027 4.7. Artemether+Lumefantrine 4.7.1. Historic Market Data & Future Forecasts, 2016-2027 4.7.2. Historic Market Data & Future Forecasts by Region, 2016-2027 Chapter 5. Artemisinin Combination Therapy Market: Regional Insights 5.1. Global Artemisinin Combination Therapy Market Data & Future Forecasts, By Region 2016-2027 5.2. North America 5.2.1. Historic Market Data & Future Forecasts, 2016-2027 5.2.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.2.3. U.S. 5.2.3.1. Historic Market Data & Future Forecasts, 2016-2027 5.2.3.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.2.4. Canada 5.2.4.1. Historic Market Data & Future Forecasts, 2016-2027 5.2.4.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.3. Europe 5.3.1. Historic Market Data & Future Forecasts, 2016-2027 5.3.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.3.3. U.K. 5.3.3.1. Historic Market Data & Future Forecasts, 2016-2027 5.3.3.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.3.4. Germany 5.3.4.1. Historic Market Data & Future Forecasts, 2016-2027 5.3.4.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.3.5. France 5.3.5.1. Historic Market Data & Future Forecasts, 2016-2027 5.3.5.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.4. Asia Pacific 5.4.1. Historic Market Data & Future Forecasts, 2016-2027 5.4.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.4.3. China 5.4.3.1. Historic Market Data & Future Forecasts, 2016-2027 5.4.3.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.4.4. India 5.4.4.1. Historic Market Data & Future Forecasts, 2016-2027 5.4.4.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.4.5. Japan 5.4.5.1. Historic Market Data & Future Forecasts, 2016-2027 5.4.5.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.4.6. South Korea 5.4.6.1. Historic Market Data & Future Forecasts, 2016-2027 5.4.6.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.5. Latin America 5.5.1. Historic Market Data & Future Forecasts, 2016-2027 5.5.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.5.3. Brazil 5.5.3.1. Historic Market Data & Future Forecasts, 2016-2027 5.5.3.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.5.4. Mexico 5.5.4.1. Historic Market Data & Future Forecasts, 2016-2027 5.5.4.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.6. Middle East & Africa 5.6.1. Historic Market Data & Future Forecasts, 2016-2027 5.6.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.6.3. UAE 5.6.3.1. Historic Market Data & Future Forecasts, 2016-2027 5.6.3.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 5.6.4. South Africa 5.6.4.1. Historic Market Data & Future Forecasts, 2016-2027 5.6.4.2. Historic Market Data & Future Forecasts, By Type, 2016-2027 Chapter 6. Company Profiles 6.1. Cipla Inc. 6.1.1. Company Description 6.1.2. Financial Highlights 6.1.3. Product Portfolio 6.1.4. Strategic Initiatives 6.2. Shelys Africa Pharmaceuticals Ltd. 6.2.1. Company Description 6.2.2. Financial Highlights 6.2.3. Product Portfolio 6.2.4. Strategic Initiatives 6.3. Ipca Laboratories Ltd. 6.3.1. Company Description 6.3.2. Financial Highlights 6.3.3. Product Portfolio 6.3.4. Strategic Initiatives 6.4. Hovid-Integrated Global Pharmaceutical Partner 6.4.1. Company Description 6.4.2. Financial Highlights 6.4.3. Product Portfolio 6.4.4. Strategic Initiatives 6.5. DENK PHARMA GmbH & Co.KG 6.5.1. Company Description 6.5.2. Financial Highlights 6.5.3. Product Portfolio 6.5.4. Strategic Initiatives 6.6. Novartis AG 6.6.1. Company Description 6.6.2. Financial Highlights 6.6.3. Product Portfolio 6.6.4. Strategic Initiatives 6.7. Guilin Pharmaceutical Co., Ltd 6.7.1. Company Description 6.7.2. Financial Highlights 6.7.3. Product Portfolio 6.7.4. Strategic Initiatives 6.8. KPC Pharmaceuticals, Inc 6.8.1. Company Description 6.8.2. Financial Highlights 6.8.3. Product Portfolio 6.8.4. Strategic Initiatives 6.9. Desano Inc. 6.9.1. Company Description 6.9.2. Financial Highlights 6.9.3. Product Portfolio 6.9.4. Strategic Initiatives 6.10. Calyx Chemicals & Pharmaceutical Ltd. 6.10.1. Company Description 6.10.2. Financial Highlights 6.10.3. Product Portfolio 6.10.4. Strategic Initiatives List of Tables Table 1 Artemisinin Combination Therapy Market Market Data & Future Forecasts, 2016-2027 (USD Million) Table 2 Artemisinin Combination Therapy Market Data & Future Forecasts, By Region, 2016-2027 (USD Million) Table 3 Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 4 Pyronaridine-Artesunate Market Data & Future Forecasts, 2016-2027 (USD Million) Table 5 Artesunate+Sulfadoxine-Pyrimethamine Market Data & Future Forecasts, 2016-2027 (USD Million) Table 6 Artesunate+Mefloquine Market Data & Future Forecasts, 2016-2027 (USD Million) Table 7 Dihydroartemisinin+Piperaquine Market Data & Future Forecasts, 2016-2027 (USD Million) Table 8 Artesunate+Amodiaquine Market Data & Future Forecasts, 2016-2027 (USD Million) Table 9 North America Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 10 North America Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 11 U.S. Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 12 U.S. Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 13 Canada Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 14 Canada Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 15 Europe Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 16 Europe Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 17 U.K. Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 18 U.K Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 19 Germany Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 20 Germany Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 21 France Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 22 France Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 23 Asia Pacific Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 24 Asia Pacific Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 25 China Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 26 China Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 27 India Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 28 India Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 29 Japan Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 30 Japan Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 31 South Korea Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 32 South Korea Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 33 Latin America Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 34 Latin America Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 35 Latin America Artemisinin Combination Therapy Market Data & Future Forecasts, By #, 2016-2027 (USD Million) Table 36 Brazil Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 37 Brazil Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 38 Mexico Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 39 Mexico Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 40 Middle East & Africa Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 41 Middle East & Africa Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 42 UAE Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 43 UAE Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) Table 44 South Africa Artemisinin Combination Therapy Market Data & Future Forecasts, 2016-2027 (USD Million) Table 45 South Africa Artemisinin Combination Therapy Market Data & Future Forecasts, By Type, 2016-2027 (USD Million) List of Figures Fig.1 Data Analysis Model Fig.2 Artemisinin Combination Therapy Market, by 2016-2027 (USD Million) Fig.3 Artemisinin Combination Therapy Market Segmentation Fig.4 Supply chain analysis Fig.5 Artemisinin Combination Therapy Market Driver Anlaysis Fig.6 Artemisinin Combination Therapy Market Restraint Analysis Fig.7 Artemisinin Combination Therapy Market Opportunity Analysis Fig.8 Porters 5 Forces Model Fig.9 PEST Analysis- Artemisinin Combination Therapy Market Fig.10 Company Market Share Analysis, 2019
Artemisinin Combination Therapy Market, By Type (2016-2027)
Pyronaridine-Artesunate
Artesunate+Sulfadoxine-Pyrimethamine
Artesunate+Mefloquine
Dihydroartemisinin+Piperaquine
Artesunate+Amodiaquine
Artemether+Lumefantrine
Artemisinin Combination Therapy Market, By Region (2016-2027)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Asia Pacific
China
India
Japan
South Korea
Latin America
Brazil
Mexico
Middle East & Africa
UAE
South Africa
Major Players Operating in the Artemisinin Combination Therapy Market:
Cipla Inc.
Shelys Africa Pharmaceuticals Ltd.
Ipca Laboratories Ltd.
Hovid-Integrated Global Pharmaceutical Partner
DENK PHARMA GmbH & Co.KG
Novartis AG
Guilin Pharmaceutical Co., Ltd
KPC Pharmaceuticals, Inc
Desano Inc.
Calyx Chemicals & Pharmaceutical Ltd.
Choose License Type
Each market study on Reports Globe will be revised based on COVID-19 impact analysis
How can we help you?
Our salient features
Best Solution
We will help you understand value propositions of various reports across numerous domains and suggest the best possible solution to suffice your research needs.
Customized Research
Our team of analysts and consultants provide assistance for customized research requirements
Max ROI
Guaranteed maximum assistance to help you get your reports at the optimum prices, thereby ensuring maximum returns on investment.
24/7 Support
24X7 availability to help you through the buying process as well as answer any of your doubts.
